La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Gentherm a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Gentherm..

Gentherm (NASDAQ:THRM) Azioni, Catena delle Opzioni

Gentherm

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

Gentherm Inc

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $36.25, along with a high estimate of $51.00 and a low estimate of $27.00. This current average has decreased by 12.65% from the previous average price target of $41.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618414_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Gentherm among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Raises &#x7C;Neutral &#x7C; $28.00&#x7C;$27.00 &#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $27.00&#x7C;$39.00 &#x7C; 
&#x7C;Luke Junk &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $39.00&#x7C;$44.00 &#x7C; 
&#x7C;Ryan Brinkman &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $51.00&#x7C;$56.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gentherm. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gentherm compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Gentherm's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Gentherm's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/THRM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gentherm analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Gentherm Better</h2>
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
<h3>A Deep Dive into Gentherm's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3M period, Gentherm faced challenges, resulting in a decline of approximately -3.82% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.34%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.4%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Gentherm's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.2%, the company showcases efficient use of assets and strong financial health.
Debt Management: Gentherm's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.43.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

THRM

Breaking Down Gentherm: 4 Analysts Share Their Views

Baird analyst Luke Junk maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and raises the price target from $27 to $28.

News

Price Target

Baird Maintains Neutral on Gentherm, Raises Price Target to $28

Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) affirms FY2025 sales outlook from $1.40 billion-$1.50 billion to $1.40 billion-$1.50 billion vs $1.43 billion estimate.

Guidance

Gentherm Affirms FY2025 Sales Guidance of $1.40B-$1.50B vs $1.43B Est

Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.46 by 10.87 percent. This is a 17.74 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $353.85 million which beat the analyst consensus estimate of $347.85 million by 1.73 percent. This is a 0.61 percent decrease over sales of $356.01 million the same period last year.

Earnings

Earnings Beats

Gentherm Q1 Adj. EPS $0.51 Beats $0.46 Estimate, Sales $353.85M Beat $347.85M Estimate

ADXN

ALEX

ALLE

AMAL

AMBP

APOG

APPF

BAFN

BCPC

BELFA

BELFB

BFST

BHLB

BWMX

CBRE

CIVB

CMCSA

CNOB

COUR

CUBI

CURB

DAIO

DGICA

DGICB

ERIE

FARO

FBIZ

FCFS

FCNCA

FFBC

FRME

GBCI

GILD

GLPI

GNFT

GOOG

GOOGL

HELE

HFWA

IBCP

INDV

INTC

ITGR

KNSL

KRNY

LADR

LYTS

MBLY

MGRC

MMSI

MOFG

Earnings Scheduled For April 24, 2025

Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) is preparing to release its quarterly earnings on Thursday, 2025-04-24. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Gentherm to report an earnings per share (EPS) of $0.46.
The market awaits Gentherm's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.39, which was followed by a 0.3% increase in the share price the next day.
Here's a look at Gentherm's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.68</td>
<td>0.66</td>
<td>0.61</td>
<td>0.43</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.29</td>
<td>0.75</td>
<td>0.66</td>
<td>0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745438513_0.png" alt="eps graph" />
<h3>Performance of Gentherm Shares</h3>
Shares of Gentherm were trading at $24.49 as of April 22. Over the last 52-week period, shares are down 50.47%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Insights on Gentherm</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Gentherm.
The consensus rating for Gentherm is Neutral, based on 3 analyst ratings. With an average one-year price target of $39.0, there's a potential 59.25% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Fox Factory Holding, Adient and American Axle &amp; Mfg Hldgs, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Fox Factory Holding, with an average 1-year price target of $30.6, suggesting a potential 24.95% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Adient, with an average 1-year price target of $16.57, suggesting a potential 32.34% downside.</li>
<li>Analysts currently favor an Neutral trajectory for American Axle &amp; Mfg Hldgs, with an average 1-year price target of $5.7, suggesting a potential 76.73% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Fox Factory Holding, Adient and American Axle &amp; Mfg Hldgs, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gentherm</td>
<td>Neutral</td>
<td>-3.82%</td>
<td>$86.10M</td>
<td>2.40%</td>
</tr>
<tr>
<td>Fox Factory Holding</td>
<td>Buy</td>
<td>6.12%</td>
<td>$101.98M</td>
<td>-0.01%</td>
</tr>
<tr>
<td>Adient</td>
<td>Neutral</td>
<td>-4.51%</td>
<td>$216M</td>
<td>0.00%</td>
</tr>
<tr>
<td>American Axle &amp; Mfg Hldgs</td>
<td>Neutral</td>
<td>-5.62%</td>
<td>$154.30M</td>
<td>-2.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Gentherm ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.
<h3>All You Need to Know About Gentherm</h3>
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
<h3>Gentherm: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Gentherm's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.82%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.34%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Gentherm's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Gentherm's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.2%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.43, Gentherm adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/THRM/earnings">To track all earnings releases for Gentherm visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Gentherm's Future Earnings

Baird analyst Luke Junk maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and lowers the price target from $39 to $27.

Baird Maintains Neutral on Gentherm, Lowers Price Target to $27

Baird analyst Luke Junk maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and lowers the price target from $44 to $39.

Baird Maintains Neutral on Gentherm, Lowers Price Target to $39

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Wednesday.
Shares of Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/THRM/news">weak quarterly results.</a>
Gentherm shares dipped 17% to $30.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) fell 14.7% to $6.40 in pre-market trading after jumping 153% on Tuesday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) declined 11.9% to $24.94 in pre-market trading following weak quarterly results.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) fell 7.7% to $3.60 in pre-market trading.</li>
<li>Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) declined 6.8% to $53.35 in pre-market trading after reporting a 6.8% YoY decline in fourth-quarter GMV and guiding for a similar YoY GMV decline in the first quarter.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) fell 5.4% to $115.50 in pre-market trading after the company reported worse-than-expected first-quarter financial results..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

BMBL

ETSY

INNV

SLSR

SUPN

Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

Gentherm shares are trading lower after the company missed Q4 EPS and revenue estimates.

Shares of Global Blue Group Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GB#NYSE">GB</a>) rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 for <a href="https://www.benzinga.com/quote/gb/analyst-ratings">$7.50 per share</a>.
Global Blue Group shares jumped 18.3% to $7.37 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cycurion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) rose 132.5% to $7.79 in pre-market trading after dipping 72% on Tuesday.</li>
<li>OSR Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares jumped 96.4% to $6.11 in pre-market trading after gaining 3% on Tuesday.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) gained 52.7% to $0.34 in pre-market trading after dipping 14% on Tuesday.</li>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) gained 43.3% to $1.55 in pre-market trading. ReShape Lifesciences shares dipped around 54% on Tuesday after the company announced a $6 million public offering of 2,575,107 units at $2.33 per unit.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares climbed 38.3% to $3.90 in pre-market trading. Sintx Technologies announced the issuance of U.S. patent no. 12,239,761 by the United States Patent and Trademark Office.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) gained 35.2% to $2.96 in pre-market trading after gaining around 12% on Tuesday.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) gained 33.1% to $0.5444 in pre-market trading after the company guided 2024 sales of $22.5 million and 2H adjusted EBITDA above $2.2 million.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) gained 22.3% to $0.1345 in pre-market after surging 57% on Tuesday.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) rose 14.5% to $8.00. MFH&#8217;s majority-owned subsidiary Aifinity Base Limited plans to manufacture advanced liquid cooling solutions for Nvidia&#xAE; chip-powered AI data centers and high-performance computing.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Movano Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) shares fell 36.4% to $3.25 in pre-market trading.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 25.5% to $0.1439 in pre-market trading after gaining around 8% on Tuesday.</li>
<li>Design Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) dipped 24.5% to $3.120 in pre-market trading.</li>
<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) fell 22% to $31.00 in pre-market trading after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 21.1% to $2.70 in today's pre-market trading. InnovAge recently reported worse-than-expected second-quarter financial results.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares tumbled 20.9% to $0.3680 in pre-market trading after dipping 35% on Tuesday. MGO Global&#8217;s stockholders approved business combination with Heidmar.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) declined 17.3% to $6.70 in pre-market trading after the company issued first-quarter revenue guidance below estimates and announced a quarter-over-quarter decline in paying app users.</li>
<li>Gentherm Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) fell 17% to $30.00 in pre-market trading following weak quarterly results.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares dipped 13.5% to $60.50 in pre-market trading after the company issued first-quarter EPS guidance below estimates.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 10.6% to $4.60 in pre-market trading following a 7% decline on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

ADTX

APTO

CYCU

DSGN

MGOL

MOVE

NEXA

NIVF

OSRH

RSLS

SINT

TRUG

Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Gentherm Sees FY25 Product Revenues Of $1.4b - $1.5B Vs. $1.54B Est.

Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) reported quarterly adjusted earnings of $0.29 per share which missed the analyst consensus estimate of $0.68 by 57.35 percent. This is a 67.78 percent decrease over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $352.91 million which missed the analyst consensus estimate of $360.29 million by 2.05 percent. This is a 3.82 percent decrease over sales of $366.93 million the same period last year.

Earnings Misses

Gentherm Q4 Adj $0.29 Misses $0.68 Estimate, Sales $352.91M Miss $360.29M Estimate

ACVA

AMPL

ANSS

APPN

BLCO

BMRN

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

JP Morgan analyst Ryan Brinkman maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and lowers the price target from $56 to $51.

JP Morgan Maintains Neutral on Gentherm, Lowers Price Target to $51

Management

Gentherm Appoints Jonathan Douyard As Executive Vice President, CFO And Treasurer

Phil Eyler to Remain as an Advisor to Gentherm through June 30, 2025.

Gentherm Plans CEO Succession In 2025; Bill Presley To Become President And CEO, And Board Director, As Of January 1, 2025

Craig-Hallum analyst Ryan Sigdahl maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Buy and lowers the price target from $85 to $65.

Craig-Hallum Maintains Buy on Gentherm, Lowers Price Target to $65

Baird analyst Luke Junk maintains Gentherm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRM#NASDAQ">THRM</a>) with a Neutral and lowers the price target from $54 to $50.

Baird Maintains Neutral on Gentherm, Lowers Price Target to $50

Guidance The Company's full-year 2024 guidance as of October 30, 2024 is shown below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>As of July 31, 2024</td>
<td>As of October 30, 2024(1)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Product Revenues</td>
<td>Low end of $1.5B – $1.6B</td>
<td>$1.45B – $1.47B</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin Rate</td>
<td>Above mid-point of 12.5% – 13.5%</td>
<td>Near mid-point of 12.5% – 13.5%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Full-year Adjusted Effective Tax Rate</td>
<td>26% – 29%</td>
<td>No change</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Capital Expenditures</td>
<td>$65M – $75M</td>
<td>No change</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="4">(1)&nbsp;Based on the current forecast of customer orders, our expectations of near-term conditions, and light vehicle production in our relevant markets decreasing at low to mid-single digit rate for full year 2024 versus 2023, and a EUR to USD exchange rate of $1.08/Euro.</td>
</tr>
</tbody>
</table>
</figure>

Gentherm 2024 Outlook: Sees Revenue Of $1.45B–$1.47B (Prior $1.5B-$1.6B) Vs. $1.50B Est

Press Releases

Gentherm Announces Updated Fireside Chat Time for 2024 Baird Global Industrial Conference

Gentherm Names Jonathan Douyard as Executive Vice President, Chief Financial Officer and Treasurer

Gentherm Announces Date for 2024 Fourth Quarter and Year-End Results News Release and Conference Call

Gentherm Reports 2024 Fourth Quarter and Full Year Results

Gentherm Reports Grant of Previously Announced CEO and CFO Inducement Awards Under Nasdaq Listing Rule

Comments

Gentherm

Gentherm (THRM) Opzioni

Gentherm (NASDAQ:THRM) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO